J 2017

ScreenPro FH: From the Czech MedPed to International Collaboration. ScreenPro FH Is a Participating Project of the EAS-FHCS

CESKA, R., Tomáš FREIBERGER, M. VACLOVA, T. ALEKSICOVA, L. VOTAVOVA et. al.

Basic information

Original name

ScreenPro FH: From the Czech MedPed to International Collaboration. ScreenPro FH Is a Participating Project of the EAS-FHCS

Authors

CESKA, R. (203 Czech Republic), Tomáš FREIBERGER (203 Czech Republic, guarantor, belonging to the institution), M. VACLOVA (203 Czech Republic), T. ALEKSICOVA (203 Czech Republic), L. VOTAVOVA (203 Czech Republic) and M. VRABLIK (203 Czech Republic)

Edition

Physiological research, Praha, Fyziologický ústav AV ČR, 2017, 0862-8408

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30105 Physiology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.324

RIV identification code

RIV/00216224:14110/17:00098437

Organization unit

Faculty of Medicine

UT WoS

000398620900010

Keywords in English

MedPed; ScreenPro FH; FHSC; Familial hypercholesterolemia; Statin intolerance

Tags

Tags

International impact, Reviewed
Změněno: 20/3/2018 14:16, Soňa Böhmová

Abstract

V originále

This article describes the evolution of our understanding of familial hypercholesterolemia (FH) in the Central, Eastern, and Southern Europe (CESE) region, and the dissemination of this understanding to other countries. Using the ScreenPro FH project as an example, we would like to illustrate the progression from national objectives, to regional networking and, finally, to international collaboration via the Familial Hypercholesterolemia Studies Collaboration (FHSC) project under the leadership of the European Atherosclerosis Society (EAS). It is essential to improve our ability to diagnose FH. In this regard, the EAS and its FHSC project must be commended for their educational and organizational activities which, above all, are dedicated to the creation of a global FH patient registry. In the CESE region, FH diagnostics and treatment situation are markedly different than in Western Europe or North America. Since the Czech MedPed project (Make Early Diagnoses to Prevent Early Deaths in Medical Pedigrees) has been so successful (with results not only comparable to, but, for some parameters, even surpassing the results of many Western countries) we decided to apply the Czech experience to the CESE region. Thus, the ScreenPro FH project was created. The aim of ScreenPro FH is to create a specialist network in the CESE region. The primary objective of the ScreenPro FH project was to dramatically reduce the number of premature deaths due to clinical complications of atherosclerosis in FH patients. At present, ScreenPro FH comprises 18 member countries with a total population of 500,000,000; which, in terms of the FH population, represents 1-2 million patients.